From Medscape News Today – by Megan Brooks
September 13, 2011 — In a pilot study, a nasal spray form of insulin, used daily for 4 months, stabilized or improved cognition, function, and cerebral glucose metabolism in adults with amnestic mild cognitive impairment (aMCI) and mild to moderate Alzheimer’s disease (AD).
“Taken together, these results provide an impetus for future clinical trials of intranasal insulin therapy and for further mechanistic studies of insulin’s role in the pathogenesis of AD,” conclude Suzanne Craft,PhD,and colleagues from the University of Washington and Veterans Affairs Puget Sound Health Care System, in Seattle.
